Fig. 5.
Dox/CpG MPs combined with Ab generate systemic immune responses that eradicate distant tumors. Seven million A20 tumor cells were injected subcutaneously in the right and left flanks of BALB/c mice. Treatment began when tumors reached 5–7 mm in largest diameter, which typically occurred at days 9–10 after tumor inoculation. Mice received PBS as control, Dox MPs (2 μg Dox), CpG MPs (1.5 μg CpG), or Dox/CpG MPs (2 μg Dox and 1.5 μg CpG; 1:1 loading) in the left tumor and three intraperitoneal doses of anti-CTLA-4 (50 μg) and anti-OX40 (200 μg) given every 3–4 days. Mice were monitored for tumor growth of both injected and distant tumors and survival. Tumor areas are mean ± SEM. Results shown are pooled from two experiments (15–20 mice/group)